Medicine is moving with incredible rapidity and access shouldn't be determined by geography.
In New Zealand, a therapy that reprograms the body's own immune cells to fight blood cancer has become standard care across much of the developed world — yet remains beyond the reach of public funding at home, forcing patients to spend fortunes or cross oceans for a chance at survival. The Malaghan Institute has quietly built a homegrown program, treating dozens through trials, and the data needed to unlock broader access may arrive before year's end. What unfolds here is a familiar tension in modern medicine: the distance between what science can do and what a health system is prepared to provide, measured not in years but in lives.
- Blood cancer patients in New Zealand face an impossible choice — join a clinical trial with limited slots, or spend hundreds of thousands of dollars traveling to Australia, the United States, or China for a treatment their own country will not fund.
- The human cost has a face: a celebrated photojournalist spent close to half a million dollars across nine months seeking CAR-T treatment in Shanghai, saw it work, watched the cancer return, and died earlier this year — his story exceptional only in its visibility.
- New Zealand's sole homegrown CAR-T program, run by the Malaghan Institute in Wellington, has treated just over 60 patients through trials, but trials are not treatment pathways, and the gap between the two is where patients fall.
- Phase two trial results expected by year's end could open the door to public funding approval for certain lymphomas within twelve to eighteen months — but the therapy's hybrid nature, part medicine, part procedure, part transfusion, is complicating the regulatory road ahead.
- Health agencies including Pharmac, Medsafe, and the Cancer Control Agency are now building an assessment framework from scratch, with an announcement on the pathway itself expected within months — a structural step, but not yet a solution.
Neill has a rare form of T cell lymphoma and a story he feels compelled to tell — not as a medical authority, but as someone who has watched the world move forward while his country stood still. The treatment that saved his life is funded across the Tasman in Australia, approved in the United States and Europe, and integrated into standard care internationally. In New Zealand, it remains accessible only through clinical trials or personal wealth.
The cost of that gap is already being counted. Jason Oxenham, a photojournalist for the NZ Herald, traveled twice to Shanghai for CAR-T therapy after a myeloma diagnosis, spending close to half a million dollars over nine months. The treatment worked, then the cancer returned. He died earlier this year. His case is not unique in its desperation — only in how many people were watching.
At the Malaghan Institute in Wellington, Professor Robert Weinkove leads New Zealand's only homegrown CAR-T program. The therapy works by extracting a patient's own immune cells, genetically reprogramming them to recognize cancer as foreign, and reinfusing them as what Weinkove calls a living drug — one that multiplies inside the body and hunts malignant tissue. The institute has treated just over 60 patients across Wellington, Auckland, and Christchurch. But trials are not the same as access, and the need far exceeds the slots.
The phase two trial is expected to complete enrollment by year's end. If results hold, public funding for certain lymphomas could follow within twelve to eighteen months. Even that optimistic timeline, however, addresses only a fraction of the problem. CAR-T therapy resists easy classification — it behaves like a medicine, a procedure, and a blood transfusion simultaneously — and New Zealand's health agencies are now building an assessment pathway from the ground up. Weinkove expects news on that framework within months.
The potential rewards are significant: roughly a third of patients achieve long-term remission, and five-year follow-up data suggests some may be cured outright. Side effects are real — inflammatory reactions, neurological complications, intensive monitoring requirements — but trial participants in New Zealand reported feeling less unwell than during previous chemotherapy. The stakes cut both ways.
Tim Edmonds of Blood Cancer NZ puts it plainly: these treatments are happening internationally, they will keep happening, and New Zealand must decide whether its patients access them at home or abroad. A ministerial oversight group is a beginning. But the true measure, Edmonds says, is whether outcomes improve — and outcomes are shaped by whether the system can deliver what modern medicine already knows how to do.
A man with a rare form of T cell lymphoma sits down to tell a story he feels compelled to share, not as a medical expert but as someone who has watched the world move on without his country. His name is Neill, and what troubles him is simple: the treatment that saved his life exists, is approved and funded across the Tasman in Australia, and yet remains locked behind clinical trial doors in New Zealand. CAR-T cell therapy—a form of immunotherapy that has become standard care for certain blood cancers internationally—remains inaccessible through public funding here, forcing patients to either join experimental programs or spend hundreds of thousands of dollars traveling overseas.
The human cost is already visible. Jason Oxenham, a celebrated photojournalist for the NZ Herald, traveled twice to Shanghai for CAR-T treatment after his myeloma diagnosis. The therapy cost close to half a million dollars across nine months. It worked initially, then the cancer returned. Oxenham died earlier this year after six years of fighting the disease. His case is not unique in its desperation, only in its visibility. Across the country, blood cancer patients face an impossible choice: wait for a clinical trial slot, or liquidate savings and travel abroad for a treatment their own health system will not provide.
At the Malaghan Institute of Medical Research in Wellington, Professor Robert Weinkove leads New Zealand's only homegrown CAR-T program. The therapy itself is elegant in concept: doctors extract a patient's own T cells—immune cells—reprogram them genetically to recognize cancer as foreign, grow them in the laboratory, and reinfuse them as what Weinkove calls a "living drug." Once back in the body, these engineered cells multiply and hunt down malignant tissue in a way that mimics natural immune response. It is, in essence, teaching the body's own defenses to win a war they were losing. The institute has treated just over 60 patients through trials operating in Wellington, Auckland, and Christchurch. But those are trials, and trials do not meet the need.
The gap between New Zealand and its neighbors is stark. Australia has multiple CAR-T products publicly funded for several indications. The United States, Europe, and other developed nations have integrated the therapy into standard treatment protocols. New Zealand has none. Weinkove describes patients becoming increasingly aware of these options and increasingly desperate to access them, traveling overseas at great personal cost. The financial burden is compounded by the difficulty of returning home for follow-up care—a practical reality that is already straining New Zealand hospitals.
Change may be coming, though slowly. The Malaghan Institute's phase two trial is expected to complete enrollment by year's end. If results are positive, there is hope the treatment could move toward approval for certain lymphomas within the next year. In what Weinkove calls an "optimistic scenario," public funding could begin within twelve to eighteen months. But even this hopeful timeline addresses only part of the problem. CAR-T therapy does not fit neatly into existing health system categories—it has characteristics of a medicine, a procedure, and a blood transfusion all at once. New Zealand health agencies including Pharmac and Medsafe are now working with the Cancer Control Agency to develop an assessment pathway for how CAR-T therapies should even be evaluated for funding. That work is ongoing. Weinkove expects news on the pathway itself within months.
The potential benefits justify the urgency. Depending on cancer type and treatment, around a third of patients achieve long-term remission. Weinkove is cautious about using the word "cure," but five-year-plus follow-up data exists, and a good fraction of patients may well be cured. Even where cure is not achieved, many experience extended remission with fewer side effects than intensive chemotherapy. Trial participants in New Zealand reported feeling less unwell than they had during previous treatments. But CAR-T is not without serious risks: inflammatory reactions that can resemble severe infection, neurological effects including confusion, and complications requiring intensive monitoring. The stakes are real on both sides.
Tim Edmonds, chief executive of Blood Cancer NZ, frames the issue as systemic. CAR-T therapy is now established standard of care in many countries, yet New Zealanders with blood cancer are increasingly forced overseas to access it. The minister's announcement of a blood cancer oversight group is a positive step, Edmonds said, but the true measure of success is improved patient outcomes. For blood cancer, outcomes are directly shaped by the system's ability to deliver modern treatments. New Zealand cannot live in a bubble while these treatments happen internationally. They are happening, they will keep happening, and the country must decide whether its patients will access them at home or abroad.
Citas Notables
Medicine is moving with incredible rapidity and access shouldn't be determined by which side of the Tasman you live on.— Neill, patient with T cell lymphoma
We don't have any publicly funded CAR T-cell treatments. We are behind our cousins across the ditch.— Professor Robert Weinkove, Malaghan Institute
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that CAR-T is available in Australia but not here? Isn't New Zealand just being cautious?
It's not caution—it's a gap. The therapy is approved and funded across the Tasman. Patients here know it exists, know it works for some people, and know they can't access it without leaving the country and spending half a million dollars. That's not caution. That's inequity.
But the treatment has serious side effects. Confusion, sepsis-like reactions. Shouldn't we be careful?
Absolutely. But careful doesn't mean absent. Other countries have found ways to offer it safely, with monitoring and protocols. We're not talking about rushing an untested drug. We're talking about a therapy that's been standard care internationally for years.
What's actually holding New Zealand back? Is it money?
It's partly money, but it's also structural. CAR-T doesn't fit into existing categories—it's part medicine, part procedure, part blood transfusion. The agencies don't even have a framework yet for how to assess it. That's being built now.
So if the Malaghan Institute's trial succeeds, funding could happen quickly?
In an optimistic scenario, yes—within a year or so for certain lymphomas. But that's only part of the picture. Myeloma patients, like the photojournalist who died, would still be left out. We'd be solving part of the problem.
What does it feel like, knowing the treatment exists but you can't access it?
It's the knowledge that matters most. Before, patients didn't know what they were missing. Now they do. And that awareness is driving people overseas, away from their families, away from their doctors, spending everything they have.